Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (TMO) is a global leader in life sciences, diagnostics, and laboratory innovation, providing essential tools for scientific research and healthcare advancements. This dedicated news hub offers investors and industry professionals timely updates on TMO's strategic initiatives, financial performance, and technological breakthroughs.
Access curated press releases and articles covering earnings reports, product launches, acquisitions, and partnerships. Our repository ensures you stay informed about developments in analytical technologies, diagnostic solutions, and biopharma services that shape the company's growth trajectory.
Discover updates across TMO's core operations: analytical instrumentation advancements, life science research tools, and specialty diagnostic innovations. Bookmark this page for streamlined access to verified information supporting informed analysis of Thermo Fisher's market position and industry impact.
Thermo Fisher Scientific (NYSE: TMO) is collaborating with the National Cancer Institute (NCI) to advance the myeloMATCH precision medicine clinical trial. This trial aims to accelerate research and treatment for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) using next-generation sequencing (NGS) technology. By quickly identifying genetic biomarkers in patients' bone marrow and blood, the trial aims to match patients to appropriate clinical studies. This approach could lead to more personalized and effective treatments, potentially increasing the survival rate for these aggressive cancers. The trial will deploy Thermo Fisher's Ion Torrent Genexus System, which offers next-day genomic testing and covers over 2,200 sites in North America.
Thermo Fisher Scientific (NYSE: TMO) has successfully completed its acquisition of Olink Holding AB (Nasdaq: OLK) for $3.1 billion. This strategic acquisition enhances Thermo Fisher's capabilities in the high-growth proteomics market, integrating Olink’s advanced proteomics solutions with Thermo Fisher's mass spectrometry and life sciences offerings.
The transaction was executed via a tender offer where Thermo Fisher's subsidiary, Orion Acquisition AB, acquired approximately 98.2% of Olink’s outstanding shares at $26.00 per share or ADS. The initial offering period expired on July 9, 2024, and a subsequent offering period will run until July 16, 2024.
Post-acquisition, Olink will be delisted from Nasdaq and deregistered, affecting the liquidity of remaining ADSs. Thermo Fisher aims to expedite scientific breakthroughs and deliver significant shareholder value through this acquisition.
Thermo Fisher Scientific (NYSE: TMO) will release its Q2 2024 financial results on July 24, 2024, before market open. An earnings conference call is scheduled for the same day at 8:30 a.m. EDT. During the call, financial performance and future expectations will be discussed. U.S. participants can dial (833) 470-1428, while international participants can use (404) 975-4839 with access code 023107. The call and replay will be available on the company's website under the 'Investors' section.
Thermo Fisher Scientific (NYSE: TMO) has extended the expiration time for its tender offer to acquire all outstanding common shares and American Depositary Shares (ADSs) of Olink Holding AB to July 9, 2024, at 5:00 p.m. New York time. The offer price remains $26.00 per share and ADS, in cash. As of June 18, 2024, approximately 84,755,040 shares and 35,240,339 ADSs have been tendered, representing about 96.2% of Olink's outstanding shares. Shareholders who have already tendered their shares or ADSs do not need to take further action. The completion of the offer is still subject to conditions detailed in the tender offer statement filed with the U.S. SEC.
Thermo Fisher Scientific (NYSE: TMO) has introduced the Thermo Scientific Stellar mass spectrometer (MS), a pioneering tool designed to enhance clinical research and precision medicine. The Stellar MS offers fast throughput, high sensitivity, and ease of use, significantly advancing translational omics research. This new tool complements the Thermo Scientific Orbitrap Astral MS by verifying key biomarkers, including peptides, metabolites, and lipids. Featuring third-party software support and integration with the Thermo Scientific Vanquish Neo UHPLC system, the Stellar MS delivers 10X quantitative sensitivity, enabling researchers to analyze five times more compounds and complete studies faster. Thermo Fisher will showcase the Stellar MS at the ASMS annual conference in June 2024.
Thermo Fisher Scientific released its 2023 Corporate Social Responsibility (CSR) report, detailing the company's commitments and progress in various areas. The report highlights the company's efforts in community support, environmental sustainability, and workforce development. Thermo Fisher employees volunteered over 100,000 hours globally and engaged more than 60,000 students in STEM competitions. The company is committed to achieving net-zero emissions by 2050, utilizing 41% renewable energy, and aims for 80% renewable electricity by 2030. Workforce initiatives include new training programs and enhanced wellness resources.
Thermo Fisher Scientific (NYSE: TMO), a leading entity in the science sector, has declared a quarterly cash dividend of $0.39 per common share.
This dividend is scheduled for payment on July 15, 2024, to shareholders recorded by June 14, 2024.
Thermo Fisher Scientific Inc. (NYSE: TMO) will have its chairman, president, and CEO present at the BofA Securities Health Care Conference on May 14, 2024. The live webcast will be available on the company's website.
Thermo Fisher Scientific, a global leader in scientific services, extends the expiration of the tender offer for all outstanding common shares and ADSs of Olink. The offer, scheduled to expire on June 18, 2024, aims to acquire Olink Holding AB for $26.00 per share in cash. As of April 30, 2024, approximately 94.3% of outstanding shares have been tendered. Completion of the offer is subject to regulatory approval.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
